GlassScriptPhysician profile
Matthew S Robin
NPI 1447499470
$7,007.25
in general payments reported to CMS, 2019-2025
25 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $149 · 2021: $518 · 2022: $932 · 2023: $1,525 · 2024: $1,234 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,351.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,917.54 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,117.70 | 2022-2024 | Caplyta |
| Axsome Therapeutics, INC. | $779.02 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $462.29 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $444.63 | 2019-2025 | Rexulti |
| Allergan, INC. | $293.78 | 2019 | |
| Corium, LLC | $276.03 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $228.01 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $190.35 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $188.99 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $179.97 | 2019-2025 | Spravato |
| Lundbeck LLC | $126.51 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $122.36 | 2025 | Austedo Xr |
| Ironshore Pharmaceuticals INC. | $104.45 | 2024 | |
| Idorsia Pharmaceuticals US INC | $98.56 | 2023 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $98.39 | 2019 | |
| Neos Therapeutics, LP | $97.23 | 2024-2025 | Adzenys Xr-Odt |
| Shire North American Group INC | $67.34 | 2019 | |
| Supernus Pharmaceuticals, INC. | $64.57 | 2022-2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $41.65 | 2025 | Cobenfy |
| Adlon Therapeutics L.P. | $31.40 | 2019-2020 | |
| Tms Neurohealth Centers INC. | $23.58 | 2025 | Tms Neurohealth Centers INC. |
| Collegium Pharmaceutical, INC. | $19.94 | 2025 | Jornay Pm |
| Alkermes, INC. | $16.90 | 2025 | Lybalvi |
| Bausch Health US, LLC | $16.06 | 2025 | Wellbutrin, Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Robin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.